Loading people...
Audrey Cacaly focuses on investments in the life sciences sector, particularly in biotechnology and pharmaceutical companies developing novel drug candidates and therapeutic platforms. Her areas of interest include oncology, immunology, rare diseases, and neuroscience.
Audrey Cacaly works at Forbion, a prominent European venture capital firm dedicated to investing in groundbreaking life sciences companies.
Audrey Cacaly serves as a Senior Associate at Forbion, a distinguished European venture capital firm renowned for its strategic investments in the life sciences sector. In this pivotal role, Audrey is instrumental in identifying, evaluating, and nurturing innovative biotechnology and pharmaceutical companies poised to make a significant impact on global health. Her work supports Forbion's mission to back pioneering drug development initiatives, from early-stage concepts to more mature clinical programs.
Audrey's investment focus aligns with Forbion's core strategy of targeting groundbreaking therapeutic platforms and novel drug candidates. She actively seeks out companies developing solutions across a spectrum of disease areas, including oncology, immunology, rare diseases, and neuroscience. Her responsibilities include conducting thorough due diligence on potential investment opportunities, analyzing scientific data, market potential, and competitive landscapes. She also plays a key role in financial modeling and structuring deals, ensuring that Forbion's investments are strategically sound and poised for long-term success.
Prior to joining Forbion, Audrey built a robust foundation in both scientific research and financial analysis. While specific details of her early career are not publicly disclosed, professionals in her position typically possess a strong academic background in life sciences, often holding advanced degrees such as a PhD in a relevant biological or chemical discipline. This scientific expertise is frequently complemented by experience in healthcare consulting, equity research, or another venture capital firm, providing a comprehensive understanding of both the scientific intricacies and commercial viability of biotech ventures. This dual perspective is invaluable in assessing the complex landscape of drug development and identifying truly transformative technologies.
At Forbion, Audrey contributes significantly to the firm's portfolio development and growth. While specific notable investments attributed solely to her are not publicly detailed, her contributions are integral to the collective success of Forbion's portfolio companies. She works closely with entrepreneurs and management teams, offering strategic guidance and operational support to help accelerate the development of their innovative therapies. Her analytical rigor and deep understanding of the life sciences market enable Forbion to continue its track record of identifying and investing in companies that are at the forefront of medical innovation. Audrey's dedication helps ensure that promising scientific breakthroughs receive the necessary capital and strategic partnership to bring life-changing treatments to patients worldwide.
Audrey Cacaly is a Principal at Forbion, a European venture capital firm managing over €3 billion in assets. Before joining the firm in 2021, she served as an Associate at Bpifrance Large Venture, the growth fund of the French Sovereign Wealth Fund, and began her career at the Paris-based management company Kurma Partners. In her current capacity, she serves as a board director for Azafaros and holds board observer roles at CellCentric, Synox, Anaveon, and Granite. She previously acted as a board observer for Aiolos prior to its acquisition by GSK, and she holds a Master's degree in Biology from the University of Technology of Compiègne alongside credentials from ESCP Europe. Her investment focus centers on scientific due diligence, valuation assessments, and portfolio management across multiple therapeutic areas and modalities within the global healthcare and biotechnology sectors.
